Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Share-based Compensation (2021 - 2025)

Kiniksa Pharmaceuticals International (KNSA) has disclosed Share-based Compensation for 5 consecutive years, with $10.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 23.34% year-over-year to $10.2 million, compared with a TTM value of $37.0 million through Dec 2025, up 20.56%, and an annual FY2025 reading of $37.0 million, up 20.56% over the prior year.
  • Share-based Compensation was $10.2 million for Q4 2025 at Kiniksa Pharmaceuticals International, up from $10.1 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $10.2 million in Q4 2025 and bottomed at $5.7 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $7.3 million, with a median of $7.0 million recorded in 2021.
  • The sharpest move saw Share-based Compensation decreased 15.37% in 2022, then rose 29.62% in 2025.
  • Year by year, Share-based Compensation stood at $6.1 million in 2021, then grew by 3.93% to $6.4 million in 2022, then grew by 21.99% to $7.8 million in 2023, then increased by 6.75% to $8.3 million in 2024, then grew by 23.34% to $10.2 million in 2025.
  • Business Quant data shows Share-based Compensation for KNSA at $10.2 million in Q4 2025, $10.1 million in Q3 2025, and $8.9 million in Q2 2025.